Intuitive Surgical, Inc. ISRG reported adjusted earnings per share (EPS) of $3.43 in the third quarter of 2019, beating the Zacks Consensus Estimate of $2.96. Adjusted EPS improved 21.2% year over year.
The Zacks Rank #3 (Hold) company recorded revenues of $1.13 billion which improved 22.5% from the prior-year quarter. The figure also outpaced the Zacks Consensus Estimate of $1.06 billion.
Instruments & Accessories
Revenues at the segment came in at $606.2 million, reflecting a year-over-year increase of 24.7% on 20% growth in da Vinci procedure volumes.
In the reported quarter, System revenues increased 23.3% year over year to $338.6 million. Notably, the company shipped 275 da Vinci Surgical Systems in the quarter.
Services revenues came in at $183.4 million, up 14.6% from the year-ago quarter.
International Sales Up
Outside the United States, revenues totaled $332 million, up 36% on a year-over-year basis. The improvement can be attributed to higher instruments and accessory revenues, driven by procedure growth and customer buying patterns.
Outside the United States, Intuitive Surgical placed 80 systems in the third quarter compared with 90 in the third quarter of 2018. Of these, 36 were in Europe, 27 in Japan, and 10 in China.
Intuitive Surgical, Inc. Price, Consensus and EPS Surprise
Intuitive Surgical, Inc. price-consensus-eps-surprise-chart | Intuitive Surgical, Inc. Quote
Adjusted gross profit in the reported quarter was $812.2 million, up 23.4% year over year. As a percentage of revenues, gross margin in the quarter was 72%, up 50 basis points (bps).
Adjusted operating income totaled $463.3 million, up 18.4% year over year. As a percentage of revenues, operating margin in the quarter was 41%, down 140 bps.
Intuitive Surgical now forecasts 2019 procedure growth in the range of 17% to 18%, compared with the previous 16% to 17%. The company has also raised the forecast for 2019 gross margin to 71-71.5% of revenues.
Intuitive Surgical ended the third quarter on a solid note. The flagship da Vinci procedures recorded solid growth in the quarter which drove the core Instrument & Accessories arm. In fact, management continues to expect strong procedure growth in 2019. The company looks to accelerate its business in China, which saw a solid third quarter as well. Overall international sales surged in the quarter. Management is optimistic about the recent approvals of the Ion endoluminal system, IRIS augmented reality product and the da Vinci SP Surgical system. Expansion in gross margin is an added positive.
On the flip side, contraction in operating margin is worrisome. Additionally, the da Vinci system is in the early stages of adoption in some of the markets outside the United States which is likely to impede placements. Intense competition in the global MedTech space is concerning as well.
Some better-ranked stocks in the broader medical space are McKesson Corporation MCK, Medtronic MDT and Varian Medical Systems VAR. While Varian Medical sports a Zacks Rank #1 (Strong Buy), McKesson and Medtronic each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for McKesson’s second-quarter fiscal 2020 revenues is pegged at $54.94 billion, suggesting 3.5% growth from the prior-year reported figure. The same for adjusted EPS stands at $3.59.
The Zacks Consensus Estimate for Varian’s fourth-quarter fiscal 2019 revenues is pegged at $853.3 million, showing a year-over-year increase of 6.4%. The same for adjusted EPS stands at $1.21, indicating an increase of 4.3% from the year-ago reported figure.
The Zacks Consensus Estimate for Medtronic’s second-quarter fiscal 2020 revenues is pegged at $7.68 billion, suggesting 2.6% growth from the prior-year reported figure. The same for adjusted EPS stands at $1.28, implying a 4.9% improvement from the year-ago reported number.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Varian Medical Systems, Inc. (VAR) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
McKesson Corporation (MCK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research